As legal cannabis transforms North America, a number of major industries are beginning to develop their own strategies for new potential products and services.

In the medical cannabis space, major pharmaceutical companies are collecting a growing body of evidence that suggests cannabis has a number of medical benefits. As big pharma begins to enter the cannabis industry, there is significant potential for top pharmaceutical companies to work together with stakeholders within the industry to develop cannabis-based medicines and treatments.

Research collected by CB2 Insights (CSE:CBII,OTCQB:CBIIF) indicates that cannabidiol (CBD) could be useful in treating a number of medical conditions, including epilepsy, multiple sclerosis, schizophrenia, migraines and arthritis. There are currently almost 400 active medical trials involving CBD around the world, with a number of major American companies like Pfizer (NYSE:PFE) and GW Pharmaceuticals (NASDAQ:GWPH) getting involved.

According to CB2 Insights, legal cannabis in the United States could save approximately US$1.1 billion on Medicaid prescriptions each year. The company believes the availability of clinical evidence could provide the missing link between patients, physicians and potential treatments. As major pharmaceutical companies begin to enter the cannabis space, they bring with them the medical data necessary to make informed healthcare decisions moving forward.

Click the image below to view the full Visual Capitalist infographic, sponsored by CB2 Insights (CSE:CBII,OTCQB:CBIIF), to learn more about the role pharmaceutical companies are taking in the legal cannabis space.

cb2 insights infographic

 


This infographic was created according to INN editorial standards to educate investors.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

Global Wellness Strategies Inc. (formerly Redfund Capital Corp.) (CSE: LOAN) (FSE: O3X4) (OTCQB: PNNRD) (“Global” or the “Company”) announces it has signed a binding letter of intent (“BLOI”) on January 22, 2021 with EntheoTech Bioscience Inc. (“ET”) a wellness psilocybin leader based in Kelowna, British Columbia and will have the option to earn up to a 19.9% interest in ET.

EntheoTech is a Canadian bioscience company focused on the research and development of products, and protocols to promote brain health, performance optimization, and global wellness, using psychoactive substances such as psilocybin, medicinal mushrooms, and other natural products.

Keep reading... Show less

The new dispensary brings expanded access for patients along Florida’s Atlantic Coast

Trulieve Cannabis Corp. (CSE: TRUL)  (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 78th nationwide. The new 4,600 sq. ft. location marks the Company’s first in the city of Sebastian and second in Indian River county expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less